Medicus Pharma (MDCX) Projected to Post Quarterly Earnings on Monday

Medicus Pharma (NASDAQ:MDCX) is projected to announce its results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). On average, analysts expect Medicus Pharma to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Medicus Pharma Price Performance

MDCX opened at $0.28 on Monday. Medicus Pharma has a one year low of $0.25 and a one year high of $3.05. The company has a fifty day moving average price of $0.37 and a 200-day moving average price of $0.61. The firm has a market capitalization of $15.82 million, a P/E ratio of -0.10 and a beta of -0.05.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MDCX. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, July 8th. Roth Capital started coverage on shares of Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Alliance Global Partners assumed coverage on shares of Medicus Pharma in a research note on Tuesday, July 28th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Medicus Pharma has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Investors Weigh In On Medicus Pharma

Large investors have recently bought and sold shares of the business. Private Advisor Group LLC raised its holdings in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after purchasing an additional 5,500 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Medicus Pharma during the 2nd quarter valued at $41,000. Commonwealth Equity Services LLC grew its holdings in Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its stake in shares of Medicus Pharma by 100.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after acquiring an additional 25,622 shares during the period.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.